#1 Clinical Trials Search in Europe

Letetresgene Autoleucel

Letetresgene Autoleucel (GSK3377794) is an innovative T-cell therapy being investigated in clinical trials for the treatment of various advanced solid tumors. This engineered T-cell therapy targets NY-ESO-1 and LAGE-1a antigens, which are found in several types of cancer. The trials aim to evaluate the safety and effectiveness of Letetresgene Autoleucel in patients with advanced cancers, including synovial sarcoma, myxoid/round cell liposarcoma, non-small cell lung cancer, and multiple myeloma.

Table of Contents

What is Letetresgene Autoleucel?

Letetresgene autoleucel, also known as lete-cel or GSK3377794, is an innovative cancer treatment that belongs to a class of therapies called engineered T-cell therapies[1]. It is designed to harness the power of your own immune system to fight cancer. This treatment is currently being studied in clinical trials for various types of advanced cancers that have not responded well to other treatments.

How Does It Work?

Letetresgene autoleucel works by targeting specific proteins called NY-ESO-1 and LAGE-1a, which are found on the surface of some cancer cells[2]. Here’s a simplified explanation of the process:

  1. Your own T-cells (a type of immune cell) are collected through a process called leukapheresis.
  2. These T-cells are then genetically modified in a laboratory to recognize and attack cancer cells that have the NY-ESO-1 or LAGE-1a proteins.
  3. The modified T-cells are then multiplied and given back to you through an intravenous (IV) infusion.
  4. Once in your body, these engineered T-cells seek out and destroy cancer cells that have the target proteins.

What Conditions Does It Treat?

Letetresgene autoleucel is being studied for the treatment of several types of advanced cancers, including:

  • Synovial Sarcoma: A rare type of soft tissue cancer that typically affects the arms, legs, or trunk[3].
  • Myxoid/Round Cell Liposarcoma: Another rare form of soft tissue cancer that usually occurs in the limbs or trunk[3].
  • Multiple Myeloma: A cancer of plasma cells, which are a type of white blood cell found in bone marrow[4].
  • Non-Small Cell Lung Cancer (NSCLC): The most common type of lung cancer[5].

These cancers must be in an advanced stage (metastatic or unresectable) and have tested positive for the NY-ESO-1 protein. Additionally, patients must have a specific genetic marker called HLA-A*02 to be eligible for this treatment.

Current Clinical Trials

Several clinical trials are currently underway to evaluate the safety and effectiveness of letetresgene autoleucel:

  • A study for previously untreated advanced synovial sarcoma or myxoid/round cell liposarcoma[6].
  • A study for previously treated advanced synovial sarcoma or myxoid/round cell liposarcoma[3].
  • A study for relapsed and refractory multiple myeloma, either alone or in combination with another drug called pembrolizumab[4].
  • A study for advanced non-small cell lung cancer[5].
  • A master protocol study that includes multiple substudies for various solid tumors[1].

How is It Administered?

The administration of letetresgene autoleucel involves several steps:

  1. Leukapheresis: Your T-cells are collected through a process similar to blood donation.
  2. T-cell Engineering: Your collected T-cells are sent to a laboratory where they are genetically modified and multiplied.
  3. Lymphodepleting Chemotherapy: Before receiving the engineered T-cells, you will receive chemotherapy drugs (usually cyclophosphamide and fludarabine) to prepare your body for the treatment[3].
  4. T-cell Infusion: The engineered T-cells are given back to you through an IV infusion, typically as a single dose[2].

Effectiveness

The effectiveness of letetresgene autoleucel is still being evaluated in clinical trials. Researchers are measuring several outcomes, including:

  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment[3].
  • Duration of Response (DOR): How long the response to treatment lasts[3].
  • Progression-Free Survival (PFS): How long patients live without their cancer getting worse[3].
  • Overall Survival (OS): How long patients live after starting treatment[1].

Early results from some trials have shown promising responses in certain patients, but more research is needed to fully understand the treatment’s effectiveness.

Potential Side Effects

As with any cancer treatment, letetresgene autoleucel can cause side effects. Some potential side effects being monitored in clinical trials include:

  • Cytokine Release Syndrome (CRS): A condition that can cause fever, chills, and other flu-like symptoms[3].
  • Neurological Effects: Such as confusion, seizures, or difficulty speaking[3].
  • Low Blood Cell Counts: Which can increase the risk of infection, bleeding, or fatigue[3].
  • Graft-versus-Host Disease: A rare but serious condition where the engineered T-cells attack healthy cells[3].

Doctors closely monitor patients for these and other side effects during and after treatment.

Future Research

Ongoing and future research aims to:

  • Determine the most effective dose and schedule for letetresgene autoleucel.
  • Identify which patients are most likely to benefit from the treatment.
  • Explore its use in combination with other cancer therapies.
  • Investigate its potential in treating other types of cancers.

As research progresses, we may gain a better understanding of how to optimize this treatment for different cancer types and patient populations.

Aspect Details
Treatment Letetresgene Autoleucel (GSK3377794)
Type Engineered T-cell therapy
Target NY-ESO-1 and LAGE-1a antigens
Cancer Types Advanced solid tumors including synovial sarcoma, myxoid/round cell liposarcoma, non-small cell lung cancer, multiple myeloma
Administration Single intravenous infusion after lymphodepleting chemotherapy
Primary Outcomes Overall Response Rate (ORR), Safety profile
Secondary Outcomes Time to Response, Duration of Response, Progression-Free Survival, Disease Control Rate
Safety Monitoring Adverse Events, Serious Adverse Events, Events of Special Interest (e.g., Cytokine Release Syndrome)
Patient Eligibility HLA-A*02+ patients with NY-ESO-1 positive tumors
Trial Phase Various (including pilot studies and master protocols)

FAQ

  • What is Letetresgene Autoleucel? Letetresgene Autoleucel (GSK3377794) is a type of engineered T-cell therapy that targets specific proteins (NY-ESO-1 and LAGE-1a) found in certain types of cancer cells. It is designed to help the immune system fight advanced solid tumors.
  • What types of cancer is Letetresgene Autoleucel being tested for? Letetresgene Autoleucel is being tested in clinical trials for various advanced solid tumors, including synovial sarcoma, myxoid/round cell liposarcoma, non-small cell lung cancer, and multiple myeloma.
  • How is Letetresgene Autoleucel administered? Letetresgene Autoleucel is administered as a single intravenous (IV) infusion after patients undergo a process called lymphodepleting chemotherapy. This chemotherapy helps prepare the body to receive the engineered T-cells.
  • What are the main goals of the clinical trials for Letetresgene Autoleucel? The main goals of the clinical trials are to evaluate the safety and effectiveness of Letetresgene Autoleucel in treating advanced solid tumors. Researchers are looking at factors such as overall response rate, time to response, duration of response, and progression-free survival.
  • Are there any side effects associated with Letetresgene Autoleucel treatment? As with any medical treatment, there may be side effects. The clinical trials are closely monitoring for adverse events, including serious adverse events and events of special interest such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. The specific side effects and their frequency are being studied as part of the trials.

Ongoing Clinical Trials on Letetresgene Autoleucel

  • Long-Term Follow-Up Study for Patients with Myxoid/Round Cell Liposarcoma, Multiple Myeloma, Non-Small Cell Lung Cancer, or Synovial Sarcoma Treated with Letetresgene Autoleucel

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy The Netherlands Spain

  • Study of Letetresgene Autoleucel for Patients with Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy The Netherlands Spain

Glossary

  • Letetresgene Autoleucel (GSK3377794): An engineered T-cell therapy that targets NY-ESO-1 and LAGE-1a antigens found in certain cancer cells. It is designed to enhance the immune system's ability to fight advanced solid tumors.
  • NY-ESO-1 and LAGE-1a: Tumor-associated proteins found in several types of cancer. These proteins are the targets of Letetresgene Autoleucel therapy.
  • T-cell therapy: A type of immunotherapy that uses T-cells (a type of white blood cell) to help the body's immune system fight cancer.
  • Lymphodepleting chemotherapy: A process used before T-cell therapy to reduce the number of existing lymphocytes in the body, making room for the engineered T-cells to work more effectively.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Adverse Events (AEs): Any undesirable experience associated with the use of a medical treatment.
  • Cytokine Release Syndrome (CRS): A condition that can occur after some immunotherapies, causing symptoms like fever, nausea, and headache due to an overactive immune response.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • HLA-A*02+: A specific type of Human Leukocyte Antigen, which is important for the immune system's ability to recognize the engineered T-cells.

References

  1. https://clinicaltrials.eu/trial/study-of-letetresgene-autoleucel-for-patients-with-synovial-sarcoma-and-myxoid-round-cell-liposarcoma/
  2. https://clinicaltrials.gov/study/NCT02992743
  3. https://clinicaltrials.gov/study/NCT06703346
  4. https://clinicaltrials.gov/study/NCT03168438
  5. https://clinicaltrials.gov/study/NCT02588612
  6. https://clinicaltrials.gov/study/NCT05993299